


Response to: Correspondence on 'Role of AMPK/mTOR-independent autophagy in clear cell renal cell carcinoma' by Lorzadeh *et al*

Milan Radovanovic,¹ Saska Vidicevic,² Jelena Tasic,² Nina Tomonjic,² Zeljka Stanojevic,² Predrag Nikic,¹ Aleksandar Vuksanovic,¹ Zoran Dzamic,¹ Uros Bumbasirevic,¹ Aleksandra Isakovic,² Vladimir Trajkovic ³

¹Urology Clinic, Clinical Center of Serbia, Belgrade, Serbia

²Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

³Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Correspondence to

Professor Vladimir Trajkovic, Institute of Microbiology and Immunology, University of Belgrade Faculty of Medicine, Belgrade, Serbia; vladimir.trajkovic@med.bg.ac.rs

Accepted 3 August 2021
Published Online First
7 September 2021



► <http://dx.doi.org/10.1136/jim-2021-002015>
► <http://dx.doi.org/10.1136/jim-2020-001524>



© American Federation for Medical Research 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Radovanovic M, Vidicevic S, Tasic J, *et al.* *J Investig Med* 2021;**69**:1485.

Dear Editor,

We read with great interest the commentary by Lorzadeh and Ghavami¹ on our article that reported AMP-activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR)-independent upregulation of autophagy in the tumor tissue of clear cell renal cell carcinoma (ccRCC) patients.² We agree with their observation that the somewhat surprising absence of a link between AMPK/mTOR signaling and autophagy induction in ccRCC might be due to the fact that we studied whole tumor tissue, containing a heterogeneous population of cancer cells, fibroblasts, vascular cells, and infiltrated immune cells.³ Moreover, intratumor heterogeneity with diverse genetic subclones within a single tumor has been increasingly recognized as an important factor influencing clinical and therapeutic outcome in ccRCC.⁴ On the other hand, genetic mutations associated with ccRCC often result in reduced AMPK and/or increased mTOR activity,⁵ and a subset of ccRCC patients responds to mTOR inhibitors,⁶ which is consistent with our findings. Also, our data that the decrease in AMPK activation was accompanied by enhanced phosphorylation of autophagy initiator Unc 51-like kinase 1 (ULK1) at the AMPK site Ser317, indicates that the latter was at least partly independent of AMPK. Possible candidates for AMPK-independent ULK1 activation and subsequent initiation of autophagy include protein kinase C and p38 mitogen-activated protein kinase, which have been found to directly phosphorylate ULK1 at AMPK sites.^{7 8} Nevertheless, exploring the AMPK/mTOR-autophagy connection at the level of specific cell types within the

tumor tissue, as proposed by Lorzadeh and Ghavami, could provide important insights into the mechanisms of ccRCC development and progression.

Contributors VT wrote the manuscript; MR, SV, JT, NT, ZS, PN, AV, ZD, UB, and AI provided critical feedback and contributed to the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

ORCID iD

Vladimir Trajkovic <http://orcid.org/0000-0002-8061-2968>

REFERENCES

- 1 Lorzadeh S, Ghavami S. Correspondence on 'Role of AMPK/mTOR-independent autophagy in clear cell renal cell carcinoma' by Radovanovic *et al.* *J Investig Med* 2021;**69**:1483–4.
- 2 Radovanovic M, Vidicevic S, Tasic J, *et al.* Role of AMPK/mTOR-independent autophagy in clear cell renal cell carcinoma. *J Investig Med* 2020;**68**:1386–93.
- 3 Mier JW. The tumor microenvironment in renal cell cancer. *Curr Opin Oncol* 2019;**31**:194–9.
- 4 López JI, Angulo JC. Pathological bases and clinical impact of intratumor heterogeneity in clear cell renal cell carcinoma. *Curr Urol Rep* 2018;**19**:3.
- 5 Massari F, Ciccarese C, Santoni M, *et al.* Metabolic alterations in renal cell carcinoma. *Cancer Treat Rev* 2015;**41**:767–76.
- 6 Faes S, Demartines N, Dormond O. Mechanistic target of rapamycin inhibitors in renal cell carcinoma: potential, limitations, and perspectives. *Front Cell Dev Biol* 2021;**9**:636037.
- 7 Miao H, Qiu F, Huang B, *et al.* PKC α replaces AMPK to regulate mitophagy: another PEDF role on ischaemic cardioprotection. *J Cell Mol Med* 2018;**22**:5732–42.
- 8 Liu Z, Sin KWT, Ding H, *et al.* p38 β MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice. *Cell Stress* 2018;**2**:311–24.